Economic Evaluation of Voriconazole versus Caspofungin for the Treatment of Invasive Aspergillosis in Spain

Abstract

Voriconazole is a more cost-effective option than caspofungin in invasive aspergillosis in patients with a bodyweight <103.42 kg.

A Systematic Review of Invasive Fungal Infection Treatment With Voriconazole And Caspofungin Among Chinese Population

“…In contrast, a lower treatment rate was reported in the RCT by Wu et al (2014) [21] for patients treated with voriconazole, although the difference was small (71.4% vs. 74.1%). None of these RCTs reported a mortality rate.…”

“…A follow-up period of 7 days was reported in Fu et al (2014) [20]. No study duration was mentioned in Wu et al (2014) [21].…”

“…Among all 12 studies, 7 reported pulmonary fungal infection [15,16,18,21] while 3 studies reported mixed infection sites [12][13][14]. Two studies did not mention any information on the site of infection [17,20].…”

“…Only one RCT reported the proportion of patients who experienced adverse events such as liver function abnormalities, renal or urinary abnormalities and visual hallucination [21]. Lower rates were observed for renal or urinary abnormalities (18% vs. 22%) and visual hallucination (7% vs. 11%) in voriconazole arms compared to caspofungin arms.…”

Clinical and economic analysis of voriconazole using for treatment of invasive aspergillosis in Russian Federation

“…В исследовании A. Dominguez-Gil et al было продемонстрировано, что использование вори-коназола при лечении ИА позволяет сократить затра-ты по сравнению с каспофунгином. Липосомальный амфотерицин В был исключен из анализа как заве-домо более дорогая стратегия [26]. В исследовании, изучавшем затратную эффективность вориконазола и липосомального амфотерицина В у реципиентов стволовых кроветворных клеток с позиции медицин-ской организации в Нидерландах, стратегии с исполь-зованием вориконазола также оказались доминирую-щими [27].…”